These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 24662435)

  • 1. Nephrotoxic effects of designer drugs: synthetic is not better!
    Luciano RL; Perazella MA
    Nat Rev Nephrol; 2014 Jun; 10(6):314-24. PubMed ID: 24662435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 'Designer drugs': update on the management of novel psychoactive substance misuse in the acute care setting.
    Smith CD; Robert S
    Clin Med (Lond); 2014 Aug; 14(4):409-15. PubMed ID: 25099844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designer Drug (DD) abuse in Poland; a review of the psychoactive and toxic properties of substances found from seizures of illegal drug products and the legal consequences thereof. Part 1--cannabinoids and cathinones.
    Biliński P; Hołownia P; Kapka-Skrzypczak L; Wojtyła A
    Ann Agric Environ Med; 2012; 19(4):857-70. PubMed ID: 23311820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Death cases involving certain new psychoactive substances: A review of the literature.
    Kraemer M; Boehmer A; Madea B; Maas A
    Forensic Sci Int; 2019 May; 298():186-267. PubMed ID: 30925344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designer drugs in psychiatric practice - a review of the literature and the recent situation in Hungary.
    Szily E; Bitter I
    Neuropsychopharmacol Hung; 2013 Dec; 15(4):223-31. PubMed ID: 24380963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The New Designer Drug Wave: A Clinical, Toxicological, and Legal Analysis.
    Abbott R; Smith DE
    J Psychoactive Drugs; 2015; 47(5):368-71. PubMed ID: 26579784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. "Not for human consumption": a review of emerging designer drugs.
    Musselman ME; Hampton JP
    Pharmacotherapy; 2014 Jul; 34(7):745-57. PubMed ID: 24710806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimulant and Designer Drug Use: Primary Care Management.
    Klega AE; Keehbauch JT
    Am Fam Physician; 2018 Jul; 98(2):85-92. PubMed ID: 30215997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bath salts and synthetic cathinones: an emerging designer drug phenomenon.
    German CL; Fleckenstein AE; Hanson GR
    Life Sci; 2014 Feb; 97(1):2-8. PubMed ID: 23911668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designer Drugs 2.0.
    Huestis MA; Tyndale RF
    Clin Pharmacol Ther; 2017 Feb; 101(2):152-157. PubMed ID: 28084644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New synthetic drugs in addictovigilance.
    Chavant F; Boucher A; Le Boisselier R; Deheul S; Debruyne D
    Therapie; 2015; 70(2):167-89. PubMed ID: 25858573
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Synthetic cannabinoids--the new "legal high" drugs].
    Berkovitz R; Arieli M; Marom E
    Harefuah; 2011 Dec; 150(12):884-7, 937. PubMed ID: 22352277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Synthetic Drugs - An Overview of Important and Newly Emerging Substances].
    Betzler F; Heinz A; Köhler S
    Fortschr Neurol Psychiatr; 2016 Nov; 84(11):690-698. PubMed ID: 27846654
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel psychoactive substances: a novel clinical challenge.
    Smith CD; Williams M; Shaikh M
    BMJ Case Rep; 2013 Aug; 2013():. PubMed ID: 23964049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Synthetic Cannabinoids Phenomenon.
    Karila L; Benyamina A; Blecha L; Cottencin O; Billieux J
    Curr Pharm Des; 2016; 22(42):6420-6425. PubMed ID: 27655416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Designer drugs 2015: assessment and management.
    Weaver MF; Hopper JA; Gunderson EW
    Addict Sci Clin Pract; 2015 Mar; 10(1):8. PubMed ID: 25928069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral fluid drug analysis in the age of new psychoactive substances.
    Øiestad EL; Øiestad ÅM; Gjelstad A; Karinen R
    Bioanalysis; 2016 Apr; 8(7):691-710. PubMed ID: 26964619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Designer drugs: mechanism of action and adverse effects.
    Luethi D; Liechti ME
    Arch Toxicol; 2020 Apr; 94(4):1085-1133. PubMed ID: 32249347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baths salts, spice, and related designer drugs: the science behind the headlines.
    Baumann MH; Solis E; Watterson LR; Marusich JA; Fantegrossi WE; Wiley JL
    J Neurosci; 2014 Nov; 34(46):15150-8. PubMed ID: 25392483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.